| scholarly article | Q13442814 |
| P2093 | author name string | Varsha Gandhi | |
| Jan A Burger | |||
| P2860 | cites work | Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia | Q28140129 |
| Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia | Q32019548 | ||
| Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial | Q33291990 | ||
| Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma | Q33343780 | ||
| Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma | Q33366403 | ||
| Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia | Q33368885 | ||
| Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. | Q33374160 | ||
| A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors | Q33374826 | ||
| Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study | Q33378194 | ||
| Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma | Q33380352 | ||
| Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia | Q33385646 | ||
| Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia | Q34402999 | ||
| New treatment options have changed the survival of patients with follicular lymphoma | Q34561857 | ||
| Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. | Q34586659 | ||
| Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. | Q34734956 | ||
| Metabolism and mechanisms of action of bendamustine: rationales for combination therapies | Q34778774 | ||
| Bendamustine: rebirth of an old drug | Q34947495 | ||
| First clinical experiences with a new cytostatic agent | Q37616384 | ||
| Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia | Q37634897 | ||
| First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia | Q38380183 | ||
| Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride | Q40234705 | ||
| Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumours | Q40616659 | ||
| Treatment of multiple myeloma with a new cytostatic agent: gamma-l-methyl-5-bis-(beta-chlorethyl)-amino-benzimidazolyl-(2)-butyric acid hydrochloride | Q43411162 | ||
| Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives | Q44096414 | ||
| High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas | Q44233737 | ||
| Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al | Q46669969 | ||
| Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. | Q51831972 | ||
| [Clinical proof is the decisive terrain. The history of alkylating agents]. | Q52933783 | ||
| Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. | Q53991694 | ||
| [Pharmacokinetics of bendamustin (Cytostasan) in B6D2F1-mice] | Q67870047 | ||
| Investigation of cross-link formation in DNA by the alkylating cytostatica IMET 3106, 3393 and 3943 | Q69379614 | ||
| On the methodology of the determination of alkylating activities of nitrogen mustards with nitrobenzylpyridine (NBP) in biological material (author's transl) | Q70984808 | ||
| Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial | Q80011702 | ||
| Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group | Q81340591 | ||
| [The pharmacokinetics of bendamustine (Cytostasane) in humans] | Q93687483 | ||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bendamustine | Q425745 |
| P304 | page(s) | 7456-7461 | |
| P577 | publication date | 2009-12-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Bendamustine in B-Cell Malignancies: The New 46-Year-Old Kid on the Block | |
| P478 | volume | 15 |
| Q33591830 | A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. |
| Q38260135 | Combination of Pim kinase inhibitor SGI-1776 and bendamustine in B-cell lymphoma |
| Q43584641 | Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. |
| Q33749652 | Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells |
| Q92691466 | High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma |
| Q37725415 | Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells |
| Q35958056 | Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia |
| Q53670141 | Renal human organic anion transporter 3 increases the susceptibility of lymphoma cells to bendamustine uptake. |
| Q37659071 | Update on therapy of chronic lymphocytic leukemia |
Search more.